BioTime Awarded $2.5 Million Grant from the Israel Innovation Authority for Continued Development of OpRegen
ALAMEDA, Calif.--(BUSINESS WIRE)--May 10, 2019--BioTime, Inc. (NYSE American and TASE: BTX), a clinical-stage biotechnology company developing cellular therapies for unmet medical…
